Osteoclasts are multinucleated cells that play a crucial role in bone resorption. The imbalance between bone resorption and bone formation results in osteoporosis. Therefore, substances that can suppress osteoclast formation are potential candidate materials for drug development or functional foods. There have been reports that extracts or purified compounds from marine micro- and macroalgae can suppress osteoclast differentiation. Symbioimine, isolated from the cultured dinoflagellate Symbiodinium sp., had suppressive effects against osteoclast differentiation in osteoclastlike cells. Norzoanthamine, isolated from the colonial zoanthid Zoanthas sp., has been shown to have anti-osteoporosis activity in ovariectomized mice. In response to marine extracts, the fucoxanthin- rich component from brown algae has been shown to have suppressive effects against osteoclast differentiation. An extract of Sargassum fusiforme has recently been shown to have anti-osteoporosis activity. This extract suppressed both osteoclast differentiation and accelerated osteoblast formation in separate in vitro experiments. In this study , we have undergone an in-silico interaction study of the each target proteins , namely TNFRSF11B, LRP5, RANKL, NOX4 , ER,PTH1R , sclerostin, NR3B1, HDAC with both reported anti-osteoporosis drugs (namely Calcitriol, Alendronate, Risedronate, Ibandronate, Zoledronate, )and phyto-chemical compounds (Symbioimine Norzoanthamine fucoxanthin, Largazole, dieckol, 1-(30,50-dihydroxyphenoxy)-7-(200,400,600-trihydroxyphenoxy) 2,4,9-trihydroxydibenzo-1,4,-dioxin , Biselyngbyaside, ikarisoside A, bolinaquinone,) obtained from algae. Interaction of phytochemical compound with target proteins shows better binding affinity as compared to drug molecules like Calcitriol and Alendronate. Thus, these marine algae and their extracts may be sources of marine medicinal foods for the prevention of osteoporosis.